Phase 3 Study of FOLFIRI Alone or With Napabucasin for Metastatic Colorectal Cancer

Share this content:
Researchers are evaluating the efficacy of FOLFIRI plus napabucasin with that of FOLFIRI alone in patients with colorectal cancer.
Researchers are evaluating the efficacy of FOLFIRI plus napabucasin with that of FOLFIRI alone in patients with colorectal cancer.

Title: A Phase III Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)1

Principal Investigator: Boston Biomedical, Inc.

Description: For this randomized phase 3 study (ClinicalTrials.gov Identifier: NCT02753127), researchers are comparing the efficacy of 5-FU, leucovorin, irinotecan (FOLFIRI) plus napabucasin with that of FOLFIRI alone in patients with previously treated metastatic colorectal cancer.

On day 1, patients in the FOLFIRI arm will receive intravenous (IV) irinotecan 180 mg/m2 and leucovorin 400 mg/m2, following bevacizumab 5mg/kg in select patients. IV 5-FU 400 mg/m2 bolus will be administered immediately after irinotecan/leucovorin, followed by 5-FU 1200 mg/m2 daily for 2 days. The treatment cycle will be repeated every 2 weeks.

Continue Reading Below

Patients in the experimental arm will receive oral napabucasin 240 mg twice daily in addition to the treatment described for the control arm.

The primary outcome is overall survival.

The estimated study enrollment is 1250 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/study/NCT02753127.

Status: Open and recruiting patients as of February 22, 2018.

This study is sponsored by Boston Biomedical, Inc.

Reference

  1. ClinicalTrials.gov. A study of napabucasin (BBI-608) in combination with FOLFIRI in adult patients with previously treated metastatic colorectal cancer (CanStem303C). NCT02753127. https://clinicaltrials.gov/ct2/show/study/NCT02753127. Accessed February 22, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs